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A B S T R A C T   
Background & aims: Plasma concentrations of bilirubin, a product of heme catabolism formed by biliverdin 
reductase A (BVRA), inversely associate with the risk of metabolic diseases including hepatic steatosis and 
diabetes mellitus in humans. Bilirubin has antioxidant and anti-inflammatory activities and may also regulate 
insulin signaling and peroxisome proliferator-activated receptor alpha (PPARα) activity. However, a causal link 
between bilirubin and metabolic diseases remains to be established. Here, we used the global Bvra gene knockout 
(Bvra–/–) mouse as a model of deficiency in bilirubin to assess its role in metabolic diseases. 
Approach & results: We fed mice fat-rich diets to induce hepatic steatosis and insulin resistance. Bile pigments 
were measured by LC-MS/MS, and hepatic lipids by LC-MS/MS (non-targeted lipidomics), HPLC-UV and Oil-Red- 
O staining. Oxidative stress was evaluated measuring F2-isoprostanes by GC-MS. Glucose metabolism and insulin 
sensitivity were verified by glucose and insulin tolerance tests, ex vivo and in vivo glucose uptake, and Western 
blotting for insulin signaling. Compared with wild type littermates, Bvra–/– mice contained negligible bilirubin in 
plasma and liver, and they had comparable glucose metabolism and insulin sensitivity. However, Bvra–/– mice 
exhibited an inflamed and fatty liver phenotype, accompanied by hepatic accumulation of oxidized tri-
acylglycerols and F2-isoprostanes, in association with depletion of α-tocopherol. α-Tocopherol supplementation 
reversed the hepatic phenotype and observed biochemical changes in Bvra–/– mice. 
Conclusions: Our data suggests that BVRA deficiency renders mice susceptible to oxidative stress-induced hepatic 
steatosis in the absence of insulin resistance.   
1. Introduction 
Non-alcoholic fatty liver disease (NAFLD) has an estimated world-
wide prevalence of 25% [1] and is associated with features of metabolic 
syndrome that confer increased risk of cardiovascular and metabolic 
diseases [2,3]. NAFLD is characterized by hepatic lipid accumulation 
and its progression leads to hepatic steatosis (fatty liver) to 
non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepato-
cellular carcinoma [4,5]. The mechanisms responsible for NAFLD 
remain unclear, although a commonly accepted hypothesis is that the 
disease progresses by multiple interrelated mechanisms, including 
insulin resistance, inflammation and oxidative stress [5]. It is conceiv-
able that modifying these factors may attenuate the development and 
progression of NAFLD [6]. 
Moderate to high concentrations of plasma bilirubin, a product of 
biliverdin reductase A (BVRA)-dependent conversion of biliverdin 
generated by heme catabolism, are associated with low incidence of 
NAFLD [7–10], insulin resistance and type 2 diabetes [11–15], sug-
gesting that bilirubin may protect against hepatic steatosis and meta-
bolic diseases. This could be achieved by the pigment’s inhibition of 
lipid oxidation alone [16,17] or via interaction with α-tocopherol 
(α-TOH, the most active form of vitamin E) [18]. Consistent with such 
antioxidant activity, we recently reported mice with very low 
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concentrations of endogenous bilirubin as a result of genetic Bvra-defi-
ciency (Bvra–/–) to have elevated circulating concentrations of oxidized 
lipids [19]. Bilirubin also has anti-inflammatory properties ameliorating 
acute and chronic hepatic inflammation [20–22]. Finally, bilirubin may 
modulate hepatic metabolism of glucose and lipids via the glycogen 
synthase kinase/peroxisome proliferator-activated receptor-α and insu-
lin receptor/PI3K/Akt signaling pathways, as suggested by experiments 
with liver-specific BVRA-deficient mice, in which plasma bilirubin 
concentrations were not shown to be regulated [23–28]. 
Despite these multiple lines of evidence for bilirubin and/or BVRA 
protecting against hepatic steatosis, the underlying mechanism remains 
unclear. We hypothesized that bilirubin/BVRA protect against NAFLD 
by decreasing oxidative stress, inflammation, and insulin resistance. To 
test this hypothesis, we fed global Bvra–/– mice high fat (HF) or high fat 
high sucrose diet (HFHS) to induce hepatic steatosis and insulin resis-
tance. We observed Bvra–/– and littermate Bvra+/+ mice to have com-
parable fasted plasma glucose and insulin, glucose and insulin tolerance, 
glucose uptake, as well as insulin signaling. However, Bvra–/– mice 
developed a fatty and inflamed liver associated with vitamin E depletion 
and increased concentrations of oxidized lipids. Administration of 
vitamin E reversed this phenotype and biochemical changes, indicating 
that bilirubin/BVRA protect mice from high fat diet-induced hepatic 
steatosis via antioxidant protection rather than prevention of insulin 
resistance. 
2. Materials and methods 
For extended Material and Methods, see online Supplementary 
materials. 
2.1. Animals 
iliverdin reductase a gene-deficient (Bvra–/–) mice have been 
described previously [19]. Bvra+/+ and Bvra–/– littermate male mice at 
7 ± 1 weeks of age were obtained from Bvra+/– x Bvra+/– breeding and 
used for all experiments. All mice were housed in a 
temperature-controlled room (Physical Containment Level 2 certifica-
tion) on a 12 h light/dark cycle and were allowed access to water and 
food ad libitum. All procedures were carried out according to the 
Australian National Health & Medical Research Council Guidelines for 
Animal Research and were approved by the Animal Care and Ethics 
Committee of the Garvan Institute of Medical Research/St Vincent’s 
Hospital. All animals received humane care according to the criteria 
outlined in the “Guide for the Care and Use of Laboratory Animals.” 
To fully characterize the metabolic phenotype of Bvra–/– mice 
required performing multiple assays. This was achieved by using mini-
mal group sizes for each parameter as predicted by power calculations, 
and by prioritizing assays that required freshly collected tissue. Group 
sizes for different assays varied from 5 to 18. This information is con-
tained in Figure Legends. 
2.2. Diets 
Animals were maintained on a standard chow containing 13% cal-
ories from fat, 22% calories from protein, and 65% calories from car-
bohydrate, 3.1 kcal/g (#27, Gordons Specialty Feeds, Australia) until 
they were allocated to a study involving a high fat (HF) or high fat high 
sucrose (HFHS) diet. Where indicated, mice were fed for up to 14 weeks 
a HF diet formulated based on D12492 (Research Diet, Inc) containing 
5.2 kcal/g with 60, 20 and 20% calories from fat, protein, and carbo-
hydrate, respectively (SF13-092, Specialty Feeds, Australia). Alterna-
tively, mice were fed for up to 6 weeks an in-house HFHS diet based on 
D12451 (Research Diets, Inc) containing 4.7 kcal/g with 47, 21 and 32% 
calories from fat, protein, and carbohydrate, respectively. The RRR- 
α-tocopheryl succinate was kindly donated by Pharma Nord, Denmark. 
The RRR-α-tocopheryl succinate was incorporated as powder in the HF 
diet obtained a concentration of RRR-α-tocopherol 0.2%, w/w in the 
diet. 
2.3. Statistical analyses 
Statistical analysis was performed using GraphPrism 8 software. 
Results are expressed as mean ± SEM. Normality of the data distribution 
was assessed (D’Agostino-Pearson test) and a Student’s t-test, 1- or 2- 
way ANOVA, Mann-Whitney, or Kruskal-Wallis test used as appro-
priate. A P-value of <0.05 was considered as statistically significant. 
3. Results 
3.1. Global BVRA deficiency does not impact glucose tolerance and 
insulin sensitivity in mice fed standard chow 
Littermate Bvra–/– and Bvra+/+ mice fed standard chow exhibited 
comparable body weight (Fig. 1A), consistent with our previous obser-
vation [19]. Bvra–/– mice had very low concentrations of hepatic bili-
rubin compared with Bvra+/+ littermates (0.3 ± 0.1 versus 2.9 ± 0.3 
pmol/mg protein) (Fig. 1B), as determined by LC-MS/MS. Instead, 
biliverdin was elevated in livers of Bvra–/– compared with Bvra+/+ mice 
(2.6 ± 0.1 versus 0.9 ± 0.1 pmol/mg protein) (Fig. 1C). Elevated con-
centrations of biliverdin were also observed in other tissues (e.g., ar-
teries) of Bvra–/– mice (unpublished data). However, Bvra+/– mice had 
similar concentrations of biliverdin and bilirubin as in Bvra+/+ litter-
mates [19]. 
There was no significant difference in non-fasted blood glucose 
concentrations in Bvra+/+ and Bvra–/– littermates 7 ± 1 weeks old 
(Fig. 1D). Similarly, blood glucose and plasma insulin concentrations 
were similar in Bvra–/– and Bvra+/+ littermates during glucose (GTT) 
and insulin tolerance tests (ITT) (Fig. 1E–I), indicating BVRA deficiency 
had no effect on glucose or insulin tolerance. Insulin resistance in adi-
pose tissue appears early in the pathogenesis of metabolic disease [29] 
and can influence whole body insulin sensitivity [30,31]. Therefore, we 
assessed glucose uptake and insulin sensitivity in adipose tissue using 
[3H] 2-deoxy-D-glucose (2-DOG) and different doses of insulin. We 
observed no significant difference in glucose uptake between the two 
genotypes (Fig. 1J). Consistent with this, we observed no significant 
difference in the expression of glucose transporter type 4 (GLUT4), the 
major insulin-regulated controller of glucose uptake in adipose, between 
Bvra+/+ and Bvra–/– mice (Fig. 1K). Moreover, BVRA deficiency did not 
affect insulin signaling in adipose explants, as indicated by the compa-
rable extent of phosphorylation of Akt and AS160, which are key reg-
ulators of insulin-stimulated glucose uptake (Fig. 1L). 
List of abbreviations: 
BOXes bilirubin/biliverdin oxidation 
BVRA biliverdin reductase A 
Bvra–/– mouse global Bvra gene knockout mouse 
CE cholesterylesters 
DB double bonds 
GLUT4 glucose transporter type 4 
GTT glucose tolerance tests 
HF high fat diet 
HFHS high fat high sucrose diet 
ITT insulin tolerance tests 
NAFLD non-alcoholic fatty liver disease 
NASH non-alcoholic steatohepatitis 
PPARα peroxisome proliferator-activated receptor alpha 
TAG triacylglycerides 
α-TOH α-tocopherol  
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3.2. BVRA deficiency does not alter high fat diet-induced glucose 
intolerance and insulin sensitivity 
Insulin resistance, e.g., impaired tolerance to glucose and insulin, has 
been observed in mice on short- and long-term high fat (HF) diets [32, 
33]. Therefore, we next investigated whether BVRA deficiency exacer-
bated glucose intolerance and insulin resistance in the setting of HF diet. 
Compared with our previous results from mice fed standard chow [19], 
HF diet had no significant effect on plasma concentrations of bile pig-
ments in Bvra+/+ and Bvra–/– mice (Fig. 2A&B). Similarly, body weights, 
fasting blood glucose concentrations, and glucose and insulin tolerance 
remained comparable between the two genotypes (Fig. 2C–I), as did in 
vivo insulin sensitivity in epididymal fat pads assessed by 2-DOG uptake 
(Fig. 2J) and phosphorylation of Akt and AS160, as well as GLUT4 
expression (Fig. 2K). There was also no difference in hepatic phos-
phorylation of Akt and GSK3β between Bvra+/+ and Bvra–/– mice 
(Fig. 2L). Finally, we examined a potential effect of BVRA deficiency on 
insulin sensitivity by providing Bvra+/+ and Bvra–/– mice high fat high 
sucrose (HFHS) diet which, due to the addition of sucrose, induces a 
more pronounced glucose intolerance [29]. Again, Bvra+/+ and Bvra–/– 
mice had comparable body weights, fasting blood glucose, and blood 
glucose and plasma insulin following injection of glucose (Supplemental 
Figs. 2A–E). Together, these findings suggest that global BVRA defi-
ciency does not affect glucose metabolism and insulin sensitivity in 
mice, whether animals are fed standard chow, or are challenged with a 
HF or HFHS diet. 
3.3. Deficiency of Bvra enhances HF diet-induced hepatic lipid 
accumulation 
Chronic feeding of fat-rich diet leads to obesity-related steatosis, a 
manifestation of the metabolic syndrome characterized by excessive 
hepatic lipid accumulation [27,34]. After 14 weeks HF diet or 6 weeks 
HFHS diet, livers in Bvra–/– mice showed evidence for lipid accumula-
tion compared with control, as indicated by increased Oil Red O-positive 
staining and the presence of lipid droplets and vacuoles (Fig. 3A and 
Supplemental Fig. 2H). HPLC analysis confirmed this observation and 
revealed that compared with Bvra+/+ mice, livers of HF-fed Bvra–/– mice 
contained more triacylglycerides (TAG, 237 ± 34 versus 551 ± 134 
nmol/mg protein) and cholesterol (25 ± 3 versus 38 ± 5 nmol/mg 
protein) (Fig. 3B and C) but not cholesterylesters (CE) (Fig. 3D). In mice 
fed HFHS diet, BVRA deficiency also increased hepatic TAG (93.8 versus 
70.4 nmol/mg protein), while cholesterol and CE were not different 
(Supplemental Figs. 2I–K). There was no significant difference in plasma 
cholesterol, CE and TAG between Bvra+/+ and Bvra–/– mice fed HF diet 
(Supplemental Figs. 3F–H). 
Development and progression of hepatic steatosis is linked to de novo 
synthesis of lipid [35]. In agreement with enhanced lipid accumulation 
in Bvra–/– mice fed HF diet, mRNA of enzymes involved in lipid syn-
thesis, i.e., acetyl-CoA carboxylase (Acaca) and fatty acid synthase 
(Fasn), but not sterol regulatory element-binding transcription factor 1 
(Srebf1), were increased compared with Bvra+/+ littermates (Fig. 3E–G). 
Liver weights, liver-to-bodyweight ratios, and plasma ALT activities 
(Fig. 3H–J) were comparable in Bvra–/– and Bvra+/+ mice. As excess fat 
can cause chronic inflammation, we determined F4/80 expression as a 
marker of Kupffer cells. Compared with Bvra+/+ mice fed HF diet, 
Bvra–/– mice had increased F4/80 (Fig. 3K) and mRNA of the 
pro-inflammatory cytokines MCP-1 and TNF-α, while mRNA of inter-
leukins-1β, -6 and -10 remained similar (Fig. 3L). 
The above results suggest that Bvra deficiency in combination with a 
HF diet enhances hepatic fat accumulation and inflammation. Fatty liver 
can progress to hepatic fibrosis. However, we observed only mild 
fibrosis, as assessed by Fast green Sirius red staining, in the liver Bvra+/+
or Bvra–/– mice fed HF diet, and no significant difference was observed 
between the genotypes (Supplementary Fig. 4). 
3.4. Bvra deficiency moderately regulates PPARα activity 
Stec and co-workers reported liver-specific BVRA deficiency caused 
hepatic steatosis via a decrease peroxisome proliferator-activated re-
ceptor-α (PPARα) activity and resulting attenuated hepatic lipid meta-
bolism [27]. Hepatic concentrations of bilirubin and biliverdin in mice 
with liver specific BVRA deficiency were not reported, which may be 
important as biliverdin has been shown to activate PPARα more effi-
ciently than bilirubin in a cellular reporter system [25]. We therefore 
first determined hepatic concentrations of bile pigments in Bvra–/– and 
Bvra+/+ mice fed a HF diet using LC-MS/MS. Global BVRA deficiency 
significantly decreased hepatic bilirubin, and this was associated with a 
commensurate increase in biliverdin, such that total bile pigment con-
centrations were comparable in the two genotypes (Fig. 4A–C). 
Consistent with this, we observed only a modest (~30%) increase in 
PPARα phosphorylation, a marker of decreased PPARα expression [27], 
in Bvra–/– compared with Bvra+/+ mice as assessed by Western blotting, 
while PPARα protein expression was not different (Fig. 4D). This in-
crease in PPARα phosphorylation was associated with a small albeit 
significant decrease in mRNA levels of some (carnitine palmitoyl-
transferase 1A, Cpt1a; cytochrome P450, family 2 (Cyp2j6) and 4, 
(Cyp4a12)), but not other PPARα-targeted genes (cluster of differentia-
tion 36, Cd36; glucose 6-phosphatase, G6pase) (Fig. 4E). Together, these 
results indicate that global BVRA deficiency at most decreases hepatic 
PPARα activity modestly, and that other factors need to be considered to 
explain the observed steatosis in Bvra–/– mice. 
3.5. Bvra deficiency increases hepatic lipid oxidation associated with a 
decrease in α-tocopherol 
We next considered non-enzymatic lipid oxidation as an alternative 
cause of hepatic lipid accumulation in Bvra–/– mice [36], as bilirubin 
protects lipids more effectively from non-enzymatic oxidation than 
biliverdin [16], and circulating lipids are more oxidized in Bvra–/– than 
Bvra+/+ mice [19]. Non-targeted lipidomic analysis of livers from 
Bvra+/+ and Bvra–/– mice fed HF diet identified 781 lipid species, with 
the top 50 regulated lipids presented as a heatmap (Fig. 5A). As can be 
seen, livers of Bvra–/– mice contained significantly more TAG (Fig. 5B), 
Fig. 1. Glucose tolerance, insulin sensitivity and insulin signaling are normal in Bvra–/– mice fed standard chow. (A) Body weights, (B, C) hepatic concentrations of 
biliverdin and bilirubin, and (D) non-fasted blood glucose in Bvra+/+ and Bvra–/– mice 7 ± 1 weeks of age. Bile pigments were measured by LC-MS/MS, with results 
normalized to protein content. (E) Blood glucose concentration following intraperitoneal glucose tolerance test (GTT, 1 g/kg glucose) in fasted (8 h) Bvra+/+ (n = 6) 
and Bvra–/– (n = 5) mice, with (F) incremental area under the curve (iAUC). (G) Plasma insulin concentrations following GTT (1 g/kg glucose) in fasted (8 h) Bvra+/+
(n = 6) and Bvra–/– mice (n = 5). (H) Blood glucose concentrations following insulin tolerance test (ITT, 0.75 U/kg insulin) in fasted (8 h) Bvra+/+ (n = 6) and Bvra–/– 
(n = 7) mice, with (I) area above the curve (AAC). (J) Protein standardized [3H] 2-deoxy-D-glucose (2-DOG) uptake into adipose tissue explants derived from the 
epididymal fat pads of Bvra+/+ (n = 5) and Bvra–/– (n = 5) mice after treatment with different concentrations of insulin. (K) Representative Western blot of glucose 
transporter type 4 (GLUT4) in adipose tissue of Bvra+/+ and Bvra–/– mice. GLUT4 expression in adipose tissue of littermate Bvra–/– and Bvra+/+ mice was quantified 
by densitometry and normalized to loading control (α-tubulin) and the expression in the Bvra+/+ group. (L) Representative Western blots of BVRA, Akt and AS160 
phosphorylation in adipose tissue of Bvra+/+ and Bvra–/– mice after treatment with different concentrations of insulin. Phosphorylation of Ser473 and Thr308 of Akt, 
and Thr642 of AS160 as assessed by densitometry, and normalized to total protein and expressed relative to Bvra+/+ mice treated with 10 nM insulin; n = 5 per 
genotype. Open and filled circles correspond to Bvra–/– and Bvra+/+ mice, respectively. Numerical results show individual data as well as mean ± SEM, with data 
analyzed for statistical difference by the Mann-Whitney test. *P < 0.05. 
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confirming the HPLC-UV data. Compared with livers from Bvra+/+ lit-
termates, Bvra–/– mice had significantly elevated concentrations of 
oxidized TAG (oxTAG) (Fig. 5C), as well as increased ratios of oxTAG to 
total TAG (Fig. 5D). We also expressed oxTAG per TAG with more than 
three double bonds (DB > 3), reasoning that TAGDB>3 contain at least 
one fatty acid with an isolated double bond and associated pair of 
bisallylic hydrogens that render lipids susceptible to oxidation. The ra-
tios of oxTAG to TAGBD>3 was significantly increased in livers of Bvra–/– 
than Bvra+/+ mice despite comparable TAGDB>3 (Fig. 5E and F). Simi-
larly, the ratio of oxidized PC (oxPC) to PCBD > 2 was significantly 
increased in livers of Bvra–/– compared with Bvra+/+ mice despite 
comparable concentrations of PC and PCDB > 2 (Supplemental Fig. 3). 
To separately probe the implied presence of oxidative stress in livers 
of Bvra–/– mice, we determined liver concentrations of α-tocopherol 
(α-TOH), the most abundant lipid-soluble antioxidant in mammals that 
protects lipids with bisallylic hydrogens from non-enzymatic oxidation. 
Compared with Bvra+/+ littermates, Bvra–/– mice had decreased ratios of 
α-TOH to TAGDB>3 (Fig. 5G), indicating decreased antioxidant protec-
tion of lipids. Interestingly, hepatic concentrations of ascorbic acid, a 
water-soluble antioxidant able to maintain α-TOH in the antioxidant 
active form [37], were not different between Bvra+/+ and Bvra–/– mice 
(Fig. 5H). We also assessed the extent of bile pigment oxidation by 
determining their end products, or BOXes, by LC-MS/MS [38,39]. The 
ratio of hepatic BOXes to TAGDB>3 was significantly decreased in Bvra–/– 
compared with Bvra+/+ mice (Fig. 5I), indicating that BVRA deficiency 
decreased the combined antioxidant protection provided by biliverdin 
and bilirubin. 
3.6. α-Tocopherol prevents hepatic lipid oxidation and lipid accumulation 
in Bvra–/– mice 
The above results suggest that non-enzymatic lipid oxidation, 
resulting from decreased endogenous lipid-soluble antioxidants (bili-
rubin and α-TOH), may cause hepatic lipid accumulation in Bvra–/– 
mice. As bilirubin cannot be administered readily to animals, we 
therefore tested whether α-TOH supplements reverses hepatic lipid 
oxidation and steatosis in BVRA deficiency by feeding Bvra+/+ and 
Bvra–/– mice a HF diet ± α-TOH (0.2%, w/w, RRR-α-TOH, the most 
active form of vitamin E) for 14 weeks. Supplementation with α-TOH 
had no effect on body weights (Fig. 6A), although it increased hepatic 
α-TOH concentrations in Bvra–/– mice (Fig. 6B). This was associated with 
a decrease in oxTAG and the ratios of oxTAG-to-total TAG and oxTAG- 
to-TAGDB>3 (Fig. 6E–G). More importantly, α-TOH supplementation 
restored wild-type hepatic concentrations of TAG (Fig. 6D) and it pre-
vented both the fatty liver and inflammatory phenotype in Bvra–/– mice, 
as assessed by Oil Red O staining (Fig. 6C) and F4/80 expression, 
respectively (Fig. 6J). 
As bilirubin and α-TOH inhibit non-enzymatic lipid oxidation and 
supplementation with α-TOH prevents such lipid oxidation and reverses 
the fatty liver phenotype, we next asked whether oxidative stress and 
associated non-enzymatic lipid oxidation causes the fatty liver 
phenotype in Bvra–/– mice fed HF diet. To do so, we used gas chroma-
tography mass spectrometry to determine hepatic concentrations of F2- 
IsoP, a specific product of non-enzymatic lipid oxidation regarded as the 
gold standard biomarker of in vivo oxidative stress. Compared with the 
corresponding wild-type control, livers of Bvra–/– mice had increased 
concentration of F2-IsoP, and α-TOH supplementation restored wild type 
concentrations of F2-IsoP (Fig. 6H). In contrast, hepatic concentrations 
of enzymatic lipid oxidation products were comparable in Bvra+/+ and 
Bvra–/– littermate mice fed a HF diet, with or without α-TOH supple-
mentation (Fig. 6I), as assessed by Ion Mobility Quadrupole Time-of- 
Flight mass spectrometry. Together, these results indicate that BVRA 
deficiency increases non-enzymatic lipid oxidation in the liver and that 
this, rather than enzymatic lipid oxidation, is a driver of both hepatic 
inflammation and formation of a fatty liver. 
4. Discussion 
This study shows that Bvra–/– mice lack bilirubin in the liver, and that 
they respond to high fat diets comparably to wildtype littermate animals 
with regards to glucose metabolism and insulin sensitivity. Despite this, 
Bvra–/– mice challenged with high fat diets develop a fatty and inflamed 
liver driven by increased non-enzymatic lipid oxidation and depletion of 
α-TOH, as restoration of hepatic α-TOH prevented such lipid oxidation, 
inflammation and steatosis. Together, the results indicate that protec-
tion from NAFLD observed in individuals with moderately to highly 
elevated bilirubin [7–10] may be due to an antioxidant action by the bile 
pigment in the liver. 
Evidence for the presence of steatosis in Bvra deficiency combined 
with a high fat diet (HF or HFHS) is based on histological (Red-O 
staining) and analytical evidence, the latter including both targeted 
(HPLC-UV) and non-targeted (LC-MS/MS) analyses. This revealed the 
presence of lipid droplets and elevated concentrations of TAG. In 
agreement with these finding, livers of Bvra–/– mice had increased 
expression of Acaca and Fasn that encode key enzymes in de novo lipo-
genesis. Moreover, catabolism of fatty acids appeared decreased, as 
mRNA of Cpt1a (an essential factor to trigger mitochondrial β-oxidation 
of long chain fatty acids) and Cyp2j6 and Cyp4a12 (catalysing the first 
step in ω-oxidation of fatty acids) [40] were decreased in Bvra–/– mice. In 
contrast, hepatic mRNA expression of Cd36 was not affected by BVRA 
deficiency, indicating that enhanced fatty acid esterification leading to 
TAG lipid droplets was likely taking place in the extracellular space 
[41]. Also, as plasma lipid concentrations were unaffected in Bvra–/– 
mice fed high fat diets, indicating that the observed steatosis was most 
likely caused by local changes in lipid metabolism. Accordingly, lipid 
peroxidation may exacerbate mitochondrial dysfunction, thereby pro-
moting lipid accumulation because of decreased β-oxidation/lipid 
metabolism [6]. 
In parallel to the observed hepatic lipid accumulation, Bvra defi-
ciency also increased hepatic inflammation, as indicated by the increase 
in F4/80 staining. As F4/80 is a macrophage marker, these results 
suggest that enhanced inflammation was likely due to the increase in 
Fig. 2. Bvra deficiency does not aggravate glucose intolerance, insulin resistance and insulin signaling in mice fed high fat (HF) diet. (A, B) Plasma biliverdin and 
bilirubin in Bvra+/+ and Bvra–/– mice fed HF diet for 12 weeks. (C) Weekly body weights of Bvra+/+ and Bvra–/– mice fed a HF diet over 12 weeks (n = 12 per 
genotype). (D) Blood glucose concentrations in fasted (8 h) Bvra+/+ (n = 11) and Bvra–/– mice (n = 11) fed HF diet for 5, 28, 56 and 84 days. (E) Blood glucose 
concentrations following GTT (1 g/kg glucose) in fasted (8 h) Bvra+/+ (n = 11) and Bvra–/– mice (n = 11) fed HF diet for 12 weeks, with (F) iAUC for GTT performed 
after HF diet for 5, 28, 56 and 84 days. (G) Plasma insulin concentrations following GTT (1 g/kg glucose) in fasted (8 h) Bvra+/+ (n = 11) and Bvra–/– mice (n = 11) 
fed HF diet for 84 days. (H) Blood glucose concentrations following ITT (0.75 U/kg insulin) in fasted (8 h) Bvra+/+ (n = 6) and Bvra–/– (n = 7) mice fed HF diet for 12 
weeks, with (I) AAC for blood glucose concentrations following ITT performed after HF diet for 5, 28, 56 and 84 days. (J) Insulin-induced 2-DOG uptake into 
epididymal adipose tissue of Bvra+/+ and Bvra–/– mice fed HF diet for 14 weeks. Data was normalized to tissue weight. (K) Representative Western blots of BVRA, 
GLUT4, and phosphorylated Akt and AS160 in epididymal adipose tissue of Bvra+/+ and Bvra–/– mice fed HF diet for 14 weeks (two independent experiments). 
Densitometry analysis of expression of GLUT4, phosphorylation of Ser473 and Thr308 of Akt, and Thr642 of AS160 in adipose tissue of Bvra+/+ (n = 12) and Bvra–/– 
(n = 11) mice. Data was normalized to total protein content or loading control (14-3-3) respectively. (L) Western blots of BVRA, phosphorylated Akt and GSK3β in 
liver of Bvra+/+ and Bvra–/– mice fed HF diet for 14 weeks (two independent experiments). (L) Densitometry analysis of phosphorylated Ser473 and Thr308 of Akt, 
and Ser9 of GSK3β in liver of Bvra+/+ (n = 12, filled circles) and Bvra–/– (n = 11, open circles) mice. Numerical results show individual data as well as mean ± SEM, 
with data analyzed for statistical difference by the Mann-Whitney test. *P < 0.05. 
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Fig. 3. Bvra deficiency enhances HF diet-induced hepatic lipid accumulation in mice. (A) Representative H&E and Oil Red O-stained liver sections. Scale bar = 100 
μm. Quantification of Oil Red O-stained area of liver sections of Bvra+/+ and Bvra–/– mice. (B–D) Concentrations of hepatic TAG, cholesterol and CE analyzed by 
HPLC-UV, with results normalized to protein. Semi-quantitative RT-PCR of hepatic Acaca, Fasn and Srebf1 mRNA transcripts (E–G), liver weight and liver-to-body- 
weight ratio (H, I), and plasma ALT (J) in male Bvra+/+ and Bvra–/– mice fed HF diet for 14 weeks. (K) Representative immunohistochemistry (IHC) of F4/80 and rat 
IgG isotype control in liver sections of Bvra+/+ and Bvra–/– mice fed HF diet, with corresponding quantitative data of F4/80 positive area. Scale bar = 100 μm. (L) 
Semi-quantitative RT-PCR of Il-1β, Il-6, Il-10, Mcp-1 and Tnf-α mRNA transcripts in liver of Bvra+/+ (n = 18, filled circles) and Bvra–/– mice (n = 17, open circles) fed 
HF diet for 14 weeks. Results shown are expressed as mean ± SEM, with data analyzed for statistical difference by the Mann-Whitney test. *P < 0.05. (For inter-
pretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
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Kupffer cells. If so, this could explain the concomitant increase in the 
expression of inflammatory cytokines TNFα and MCP-1 that potentially 
exacerbate hepatic inflammation via cross talk with hepatocytes. 
We are not aware of previous studies reporting the presence of bili-
verdin in liver of wildtype mice or other mammals, whereas we observed 
~25% of hepatic bile pigments to be present as biliverdin in livers of 
Bvra+/+ mice, independent of the diet used. This is different to the sit-
uation in plasma, where biliverdin accounts for only ~1% of bile pig-
ments. In fact, biliverdin is commonly thought to be essentially 
undetectable in vivo [42] due to the kinetic efficiency of BVRA. Bile 
pigments were detected by an LC-MS/MS-based method, providing high 
analytical specificity. The presence of biliverdin in the liver of C57BL/6J 
mice fed standard chow or high fat diet indicates that available BVRA 
activity is insufficient to ‘deal with’ the amounts of biliverdin formed. 
Our data also suggests a potential limitation to the perceived role of 
BVRA in ‘releasing’ biliverdin from heme oxygenase to ‘accelerate’ the 
rate-limiting step in heme degradation by the oxygenase [43]. In any 
case, our findings warrant further investigation into the potential 
biological activities of biliverdin in the liver. 
We provide direct evidence that Bvra deficiency increases oxidative 
stress and that this results in the oxidation of hepatic lipids. Evidence for 
the presence of oxidative stress comes from both, the observed decrease 
in hepatic concentrations of α-TOH and the increase in F2-IsoP, the latter 
regarded as the gold standard biomarker of in vivo oxidative stress [44]. 
Non-targeted lipidomics and ion mobility LC-MS analyses revealed that 
the inflammatory hepatic steatosis in the Bvra–/– mice was accompanied 
by an increase in enzymatically oxidized fatty acids in the form of oxTAG 
and oxPC. As expected, the concentration of these enzymatic lipid 
oxidation products was unaffected by α-TOH supplementation, and 
therefore not likely responsible for the observed steatosis in BVRA 
deficiency. 
In contrast to enzymatic lipid oxidation, BVRA deficiency increased, 
and α-TOH supplementation decreased, the hepatic concentration of the 
non-enzymatic lipid oxidation products F2-IsoP. This suggests non- 
enzymatic lipid oxidation as a cause for the observed inflammatory 
steatosis in Bvra–/– mice. In support of this interpretation, in vivo 
Fig. 4. Bvra and bilirubin deficiency modestly regulates hepatic PPARα activity in mice fed HF diet. (A, B, C) Hepatic concentration of biliverdin, bilirubin and total 
bile pigments in Bvra+/+ and Bvra–/– mice determined by LC-MS/MS with results normalized to protein. (D) Representative Western blots of PPARα phosphorylation 
in liver of Bvra+/+ and Bvra–/– mice fed HF diet for 14 weeks. Densitometry analysis of expression of hepatic PPARα and phosphorylation of Ser73. Data was 
normalized to total protein content or loading control (Actin). (E) Semi-quantitative RT-PCR of Cpt1a, Cyp2j6, Cyp4a12, Cd36, G6pase mRNA transcripts in liver of 
Bvra+/+ (n = 13, filled circles) and Bvra–/– mice (n = 11, open circles) fed HF diet for 14 weeks. Open and filled circles correspond to Bvra–/– and Bvra+/+ mice 
respectively. Results shown are expressed as mean ± SEM, with data analyzed for statistical difference by the Mann-Whitney test. *P < 0.05. 
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Fig. 5. Bvra deficiency depletes hepatic α-tocopherol (α-TOH) and increases lipid oxidation in mice fed HF diet. (A) Untargeted lipidomic analysis of livers from 
Bvra+/+ and Bvra–/– mice. (B–F) Concentrations of hepatic total TAG, oxidized TAG (oxTAG), ratio of oxTAG-to-total TAG, ratio of TAG containing fatty acids with 
more than three double bonds (TAGDB>3) to total TAG, and oxTAG-to-TAGDB>3 ratio in Bvra+/+ and Bvra–/– mice. Lipids were determined by LC-MS/MS and their 
concentrations assessed by area comparison of individual lipid signals with that of the corresponding internal lipid standard. (G) Ratio of hepatic α-TOH-to-TAG and 
α-TOH-to-TAGDB>3 in Bvra+/+ and Bvra–/– mice. (H) Hepatic ascorbate in Bvra+/+ and Bvra–/– mice determined by HPLC. (I) Ratio of oxidation products of bile 
pigments (BOXes)-to-TAGDB>3 and BOXes -to-bile pigments in liver of Bvra+/+ and Bvra–/– mice. Results of hepatic TAG and oxTAG were normalized to tissue weight 
(mg), while ascorbate was normalized to protein. Results shown are mean ± SEM with data analyzed for statistical difference using the Mann-Whitney test. *P < 0.05. 
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Fig. 6. α-Tocopherol prevents hepatic 
lipid accumulation and lipid oxidation in 
Bvra–/– mice fed HF diet for 14 weeks. (A) 
Body weights of Bvra+/+ and Bvra–/– mice 
fed a HF diet ± α-TOH supplement (0.2% 
RRR-α-TOH, w/w). (B) Ratio of hepatic 
α-TOH-to-TAG and α-TOH-to-TAGDB>3 in 
Bvra+/+ and Bvra–/– mice fed HF diet ±
α-TOH. α-TOH was measured by LC-MS/ 
MS and results normalized to tissue 
weight (mg). (C) Representative H&E and 
Oil Red O-stained liver sections of Bvra+/+
and Bvra–/– mice fed HF ± α-TOH. Scale 
bar = 100 μm, with quantification also 
provided. (D–G) Concentrations of hepatic 
total TAG, oxTAG, oxTAG-to-total TAG, 
and oxTAG-to-TAGDB>3 in Bvra+/+ and 
Bvra–/– mice fed HF ± α-TOH. (H) Hepatic 
F2-IsoP in Bvra+/+ and Bvra–/– mice fed HF 
diet ± α-TOH. (I) Enzymatic lipid oxida-
tion products in the liver of Bvra+/+ and 
Bvra–/– mice fed HF diet ± α-TOH. TAG 
and oxTAG were measured by untargeted 
lipidomic analysis using LC-MS/MS, F2- 
IsoP were measured by GC-MS and enzy-
matic lipid oxidation products by ion 
mobility Q-TOF LC/MS. (J) IHC of F4/80 
and rat IgG isotype control in liver sections 
of Bvra+/+ and Bvra–/– mice fed HF diet ±
α-TOH, with corresponding quantitative 
data of F4/80 positive area. Scale bar =
100 μm. Numerical results show individual 
data as well as mean ± SEM, with data 
analyzed for statistical difference using the 
Kruskal Wallis test. *P < 0.05. (For inter-
pretation of the references to colour in this 
figure legend, the reader is referred to the 
Web version of this article.)   
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administration of a free radical generator has been reported to cause 
non-enzymatic lipid oxidation and a fatty liver in mice [36]. Oxidative 
stress has also been implicated in the pathogenesis of NAFLD [6]. If 
oxidative stress and resulting non-enzymatic lipid oxidation is causally 
involved in the development of NAFLD, supplementation of lipid-soluble 
radical scavenging antioxidants should be effective in suppressing the 
disease. We addressed this question by supplementing Bvra–/– mice fed 
high fat diet with RRR-α-TOH. This not only inhibited non-enzymatic 
lipid oxidation but also reversed hepatic steatosis and inflammation. 
Our findings may have translational implications, because supplemen-
tation of humans with 800 IU/day α-TOH has been reported to inhibit 
the total NAFLD activity score in non-diabetic adults with nonalcoholic 
steatohepatitis [45]. A recent practice guidance for the diagnosis and 
management of NAFLD by the American Association for the Study of 
Liver Diseases [46] stated “Vitamin E (RRR α-tocopherol) administered 
at a daily dose of 800 IU/day improves liver histology in nondiabetic 
adults with biopsy-proven NASH and therefore may be considered for 
this patient population. Risks and benefits should be discussed with each 
patient before starting therapy. Until further data supporting its effec-
tiveness become available, vitamin E is not recommended to treat NASH 
in diabetic patients, NAFLD without liver biopsy, NASH cirrhosis, or 
cryptogenic cirrhosis”. 
The present study used BVRA-deficient mice as a model of bilirubin 
deficiency. A limitation of this model is that it does not allow to 
immediately assign any observed phenotype to either the absence of 
BVRA or bilirubin, or both. Previous studies suggested that in addition to 
catalysing the reduction of biliverdin to bilirubin, BVRA may also 
regulate glucose metabolism and insulin signaling [24,28,47,48]. Stec 
and co-workers reported hepatic steatosis and impaired hepatic insulin 
signaling in liver-specific BVRA knockout mice fed the same high fat diet 
for the same duration as in the present work [27]. They also reported 
BVRA and its enzymatic product bilirubin to attenuate hepatic steatosis 
via the activation of PPARα signaling pathway to promote β-oxidation of 
fatty acids [25–27]. We also observed global BVRA deficiency to indi-
rectly decrease β-oxidation. However, any effect on the PPARα signaling 
pathway was modest, and Bvra–/– mice fed a high fat diet had compa-
rable insulin sensitivity and signaling compared to littermate control 
animals, as assessed by multiple parameters, and using two different 
types of high fat diets. Others reported a deficiency in PPARα to not alter 
insulin sensitivity in mice maintained on high fat diet, as assessed by 
hyperinsulinemic-euglycemic clamp studies [49]. These results indicate 
potential differences between the two mouse models and suggest that 
the resulting phenotypic differences may be explained by differences in 
hepatic bilirubin concentrations and/or the fact that BVRA can activate 
or inhibit glucose uptake and insulin signaling [48]. Further studies are 
required to establish a role for BVRA in in vivo glucose metabolism and 
insulin sensitivity. 
Hepatic steatosis is widely believed to result in insulin resistance [4, 
50]. However, there is also evidence indicating that hepatic lipid 
accumulation is insufficient to cause, and can occur independent of, 
insulin resistance [51,52], especially hepatic insulin resistance [53]. 
Intrahepatic accumulation of TAG may be more a marker than cause of 
insulin resistance, as exemplified by patients with familial hypo-
betalipoproteinemia in whom hepatic steatosis is dissociated from in-
sulin resistance [54]. 
Bilirubin is a potent non-enzymatic antioxidant in its own right for 
both the lipid and aqueous phase [16], and the pigment can also afford 
effective inhibition of lipid oxidation through interaction with α-TOH 
[18]. Therefore, it is tempting to speculate that the observed increase in 
non-enzymatic lipid oxidation in the liver of Bvra–/– mice was due to 
their lack of bilirubin rather than the absence of BVRA. Consistent with 
this interpretation, we reported previously that lipid oxidation products 
are increased in blood plasma of Bvra–/– compared with Bvra+/+ mice 
fed standard chow [19]. Also, our observation that products of bilir-
ubin/biliverdin oxidation (BOXes) are present in livers of Bvra+/+ mice 
fed high fat diet directly shows that hepatic bilirubin acts as an 
antioxidant in vivo. Interestingly, we detected biliverdin in the livers of 
both Bvra+/+ and Bvra–/– mice. As biliverdin also has antioxidant ac-
tivity [16], and its liver concentrations were higher in Bvra–/– than 
wildtype mice, it is conceivable that biliverdin may compensate for 
bilirubin as a non-enzymatic antioxidant. Inconsistent with this idea, 
however, hepatic concentrations of α-TOH and BOXes were lower and 
non-enzymatic lipid oxidation products were higher in livers of Bvra–/– 
compared with Bvra+/+ mice. Also, in vitro biliverdin has lower anti-
oxidant activity than bilirubin [16]. Surprisingly, we observed no 
change in hepatic ascorbate between Bvra–/– and Bvra+/+ mice. In 
contrast to bilirubin, ascorbate requires α-TOH to protect lipids from 
oxidation, so that the depletion of hepatic α-TOH in Bvra–/– mice may 
explain why tissue concentrations of ascorbate were unaffected and 
substantial non-enzymatic lipid oxidation, especially within large lipid 
droplets, took place despite the presence of normal concentrations of 
ascorbate. A prerequisite for this may be that lipid oxidation is initiated 
within the ‘lipid phase’, by a presently unknown cause. 
The almost complete systemic absence of bilirubin makes Bvra–/– 
mice a useful tool to address the physiological roles of bilirubin, espe-
cially as provision of exogenous bilirubin is not a feasible approach due 
to the pigment’s effective insolubility in physiological buffers. By com-
parison, there is currently no evidence that tissue-specific BVRA knock- 
out affects bilirubin concentrations systemically or locally, so that this 
approach is not suitable to directly assess the biological roles of bili-
rubin. A complicating factor of Bvra–/– mice is that they have elevated 
concentrations of biliverdin in plasma, bile, and other tissues, including 
liver and arteries (unpublished data), and the physiological roles of 
biliverdin in mammals are not well understood. Pharmacological in-
duction of hyperbilirubinemia by atazanavir (that inhibits bilirubin 
conjugation), has been reported to protect against metabolic and car-
diovascular diseases in HIV patients [55,56]. Therefore, pharmacolog-
ical tools may be useful in unravelling the mechanisms underlying the 
protective effects of bilirubin, as well as in its translation as novel 
strategies for the treatment of cardiovascular and metabolic diseases. 
Although Bvra mRNA and BVRA protein are completely absent in Bvra–/– 
mice, very low concentrations of bilirubin were detected in the liver, 
plasma, and other tissues, consistent with our previous observation [19]. 
The residual bilirubin detected in Bvra–/– mice may be due to biliverdin 
reductase B (BVRB), which is present in mammals and can also reduce 
biliverdin to bilirubin. 
In conclusion, our findings for the first time, support the hypothesis 
proposed nearly 35 years ago [16] that bilirubin has a biological func-
tion by acting as a physiological antioxidant. Our metabolic character-
ization of Bvra–/– mice indicates that the inflammatory steatosis is 
caused by the local depletion of the lipid-soluble antioxidants α-TOH 
and bilirubin, and its associated non-enzymatic lipid oxidation. As high 
concentrations of supplemented α-TOH may increase the risk of 
all-cause mortality [57,58], prostate cancer [59], and hemorrhagic 
stroke [60], elevating the endogenous antioxidant bilirubin deserves 
consideration as a potential alternative treatment in the management of 
NALFD in patients where conventional management fails. 
Future investigations will utilize the Bvra deficient mouse line to 
establish a potential causative link between bilirubin and protection 
against cardiovascular disease, as increased plasma bilirubin is also 
inversely associated to low risk of cardiovascular disease. 
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